Florham Park, New Jersey-based biopharmaceutical firm, Phathom Pharmaceuticals, Inc., is dedicated to the development and commercialization of innovative treatments for gastrointestinal diseases. The company boasts the rights to an investigational potassium-competitive acid blocker (P-CAB) that is poised to revolutionize acid secretion in the stomach. Its geographic reach extends across the United States, Europe, and Canada. Phathom is also vigorously developing vonoprazan for the treatment of erosive gastroesophageal reflux disease, as well as its use in combination with antibiotics for the treatment of Helicobacter pylori infection. Established in 2018, Phathom Pharmaceuticals, Inc. is steadfast in its commitment to becoming a leading force in the quest for groundbreaking solutions to gastrointestinal diseases.
Phathom Pharmaceuticals's ticker is PHAT
The company's shares trade on the NASDAQ stock exchange
They are based in Florham Park, New Jersey
There are 11-50 employees working at Phathom Pharmaceuticals
It is phathompharma.com
Phathom Pharmaceuticals is in the Healthcare sector
Phathom Pharmaceuticals is in the Biotechnology industry
The following five companies are Phathom Pharmaceuticals's industry peers: